Ignite Creation Date:
2024-05-06 @ 8:24 PM
Last Modification Date:
2024-10-26 @ 3:27 PM
Study NCT ID:
NCT06372457
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-04-18
First Post:
2024-04-15
Brief Title:
COLLIGO-HCM A Multinational Observational Study of the Real-World Effectiveness of Mavacamten Among Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy oHCM
Sponsor:
Bristol-Myers Squibb
Organization:
Bristol-Myers Squibb
Study Overview
Official Title:
mavaCamten ObservationaL evIdence Global cOnsortium in HCM COLLIGO-HCM
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
COLLIGO-HCM
Brief Summary:
COLLIGO-HCM is a global observational study that will conduct observational research of hypertrophic cardiomyopathy HCM treatment in real-world clinical practice
Detailed Description:
The mavaCamten ObservationaL evIdence Global cOnsortium in hypertrophic cardiomyopathy COLLIGO-HCM is a global observational research initiative aiming to describe the real-world outcomes of treatments for obstructive hypertrophic cardiomyopathy HCM including mavacamten
This retrospective study uses data from existing medical records and electronic registries from HCM centers around the world
This retrospective study uses data from existing medical records and electronic registries from HCM centers around the world
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None